Torello M Lotti
Overview
Explore the profile of Torello M Lotti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bertoli M, Sadoughifar R, Schwartz R, Lotti T, Janniger C
Dermatol Ther
. 2020 Jul;
33(6):e14055.
PMID: 32700775
Female pattern hair loss is a common form of hair loss in women that increases in incidence with age. The etiology is unknown with numerous factors identified that influence its...
2.
Franca K, Lotti T
Adv Exp Med Biol
. 2017 Nov;
996:123-134.
PMID: 29124696
Psycho-Neuro-Endocrine-Immunology (P.N.E.I.) is a scientific field of study that investigates the link between bidirectional communications among the nervous system, the endocrine system, and the immune system and the correlations of...
3.
Lotti T, Gianfaldoni S
Adv Exp Med Biol
. 2017 Nov;
996:105-110.
PMID: 29124694
The exposure to ultraviolet radiations and visible light, or phototherapy, is a well-known therapeutic tool available for the treatment of many dermatological disorders. The continuos medical and technological progresses, of...
4.
Lee B, Schwartz R, Hercogova J, Valle Y, Lotti T
Dermatol Ther
. 2012 Dec;
25 Suppl 1:S44-56.
PMID: 23237038
Vitiligo is a depigmenting disorder stemming from melanocyte loss or dysfunction. It has a complex, multifaceted etiology. We constructed a "vitiligo road map," consisting of basic science, clinical, and treatment...
5.
Pietrzak A, Bartosinska J, Hercogova J, Lotti T, Chodorowska G
Dermatol Ther
. 2012 Dec;
25 Suppl 1:S41-3.
PMID: 23237037
Vitiligo is an acquired, depigmenting skin disease with still unclear, multifactorial etiopathogenesis. However, there is growing evidence that vitiligo affects not only the skin but it may also be connected...
6.
Lotti T, Hercogova J, Schwartz R, Tsampau D, Korobko I, Pietrzak A, et al.
Dermatol Ther
. 2012 Dec;
25 Suppl 1:S32-40.
PMID: 23237036
Vitiligo is a manageable disease. However, current vitiligo treatments can be considered suboptimal as they do not guarantee high efficacy and cannot be standardized for most patients. Recently, combination therapies...
7.
Hercogova J, Schwartz R, Lotti T
Dermatol Ther
. 2012 Dec;
25 Suppl 1:S10-6.
PMID: 23237033
The classification of vitiligo is mandatory for clinical and research purposes. Although the etiology and pathobiology of vitiligo remain unknown, a working classification of vitiligo is imperative for the scientific...
8.
Valle Y, Lotti T, Hercogova J, Schwartz R, Korobko I
Dermatol Ther
. 2012 Dec;
25 Suppl 1:S1-9.
PMID: 23237032
A global interest in therapies for neglected diseases is rising, but traditional biopharma research and development (R&D) process is prohibitively expensive to justify cost of their development. Vitiligo is a...
9.